Liposomal irinotecan plus chemotherapy and targeted therapy for advanced bile duct cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of a targeted drug (lenvatinib), an immunotherapy (PD-1 inhibitor), and chemotherapy given directly into the liver's blood supply for people with advanced intrahepatic cholangiocarcinoma (a type of bile duct cancer that starts in the liver). The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a type of bile duct cancer inside the liver that cannot be removed with surgery or has spread.
- Your liver function must be fairly good (Child-Pugh class A or borderline B).
- You must not have had previous chemotherapy for advanced disease (prior treatment after surgery is allowed if it was over 6 months ago).
- You must be generally active and able to take care of yourself (ECOG score 0 or 1).
- You must have at least one tumor that can be measured on scans.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding a combination of immunotherapy (adebrelimab), a targeted drug (apatinib), and chemotherapy into the liver artery (HAIC) before and after surgery can help people with resectable intrahepatic cholangiocarcinoma (a type of bile duct cancer). The goal is to see if this approach improves outcomes.
This trial tests a combination of chemotherapy (gemcitabine and cisplatin) with the targeted therapy lenvatinib and the immunotherapy adebrelimab for people with advanced bile duct cancer that cannot be removed by surgery. It aims to see if this combination works better than standard treatments.
This study tests a combination of liver-directed therapy (D-TACE-HAIC), an immunotherapy drug (Envafolimab), and a targeted therapy pill (Lenvatinib) for people with a type of liver cancer (intrahepatic cholangiocarcinoma) that cannot be surgically removed. The goal is to see if this combination can shrink or control the cancer.
This Phase 3 study tests whether toripalimab (an immunotherapy) combined with lenvatinib and chemotherapy works better than standard treatment for advanced intrahepatic cholangiocarcinoma. It aims to help people live longer and/or control the cancer more effectively.
This trial tests a new combination of three drugs (adebrelimab, surufatinib, and liposomal irinotecan) given directly into the liver artery for advanced intrahepatic cholangiocarcinoma. The goal is to see if this approach can shrink or control the cancer.
This trial tests combining a liver-directed chemotherapy infusion (HAIC) with immunotherapy to shrink advanced bile duct cancer that cannot be removed surgically. The goal is to slow tumor growth and improve survival.
Hear when a new Intrahepatic Cholangiocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.